264 related articles for article (PubMed ID: 35022913)
21. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
22. Structural insight into Mycobacterium tuberculosis maltosyl transferase inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations.
Sengupta S; Roy D; Bandyopadhyay S
J Biomol Struct Dyn; 2015; 33(12):2655-66. PubMed ID: 25669125
[TBL] [Abstract][Full Text] [Related]
23. Ursolic acid acetate and iso-mukaadial acetate bind to Plasmodium falciparum Hsp90, abrogating its chaperone function in vitro.
Nndwammbi AAT; Dongola TH; Shonhai A; Mokoena F; Pooe OJ; Simelane MBC
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5179-5192. PubMed ID: 38252299
[TBL] [Abstract][Full Text] [Related]
24. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Chaudhari HK; Pahelkar A
Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
[TBL] [Abstract][Full Text] [Related]
25. 3-Aryl-substituted imidazo[1,2-a]pyridines as antituberculosis agents.
Karale UB; Shinde AU; Babar DA; Sangu KG; Vagolu SK; Eruva VK; Jadav SS; Misra S; Dharmarajan S; Rode HB
Arch Pharm (Weinheim); 2021 Oct; 354(10):e2000419. PubMed ID: 34185337
[TBL] [Abstract][Full Text] [Related]
26. In silico Screening of Food and Drug Administration-approved Compounds against Trehalose 2-sulfotransferase (Rv0295c) in Mycobacterium tuberculosis: Insights from Molecular Docking and Dynamics Simulations.
Sharma D; Gautam S; Srivastava N; Bisht D
Int J Mycobacteriol; 2024 Jan; 13(1):73-82. PubMed ID: 38771283
[TBL] [Abstract][Full Text] [Related]
27. Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays.
Zhang Q; Han J; Zhu Y; Yu F; Hu X; Tong HHY; Liu H
J Comput Aided Mol Des; 2023 Dec; 37(12):695-706. PubMed ID: 37642861
[TBL] [Abstract][Full Text] [Related]
28. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
[TBL] [Abstract][Full Text] [Related]
29. Antimycobacterial activity of methanolic plant extract of Artemisia capillaris containing ursolic acid and hydroquinone against Mycobacterium tuberculosis.
Jyoti MA; Nam KW; Jang WS; Kim YH; Kim SK; Lee BE; Song HY
J Infect Chemother; 2016 Apr; 22(4):200-8. PubMed ID: 26867795
[TBL] [Abstract][Full Text] [Related]
30. Molecular modelling and competitive inhibition of a Mycobacterium tuberculosis multidrug-resistance efflux pump.
Scaini JLR; Camargo AD; Seus VR; von Groll A; Werhli AV; da Silva PEA; Machado KDS
J Mol Graph Model; 2019 Mar; 87():98-108. PubMed ID: 30529931
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
Saxena S; Abdullah M; Sriram D; Guruprasad L
J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
[TBL] [Abstract][Full Text] [Related]
32. Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.
Lu X; Williams Z; Hards K; Tang J; Cheung CY; Aung HL; Wang B; Liu Z; Hu X; Lenaerts A; Woolhiser L; Hastings C; Zhang X; Wang Z; Rhee K; Ding K; Zhang T; Cook GM
ACS Infect Dis; 2019 Feb; 5(2):239-249. PubMed ID: 30485737
[TBL] [Abstract][Full Text] [Related]
33. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
34. Natural Metabolite Ursolic Acid as an Inhibitor of Dormancy Regulator DosR of
Jee B; Sharma PP; Goel VK; Kumar S; Singh Y; Rathi B
Curr Comput Aided Drug Des; 2023; 19(6):425-437. PubMed ID: 36722482
[TBL] [Abstract][Full Text] [Related]
35. Ursolic and oleanolic acids as antimicrobial and immunomodulatory compounds for tuberculosis treatment.
Jiménez-Arellanes A; Luna-Herrera J; Cornejo-Garrido J; López-García S; Castro-Mussot ME; Meckes-Fischer M; Mata-Espinosa D; Marquina B; Torres J; Hernández-Pando R
BMC Complement Altern Med; 2013 Oct; 13():258. PubMed ID: 24098949
[TBL] [Abstract][Full Text] [Related]
36. In silico design of novel quinazoline-based compounds as potential Mycobacterium tuberculosis PknB inhibitors through 2D and 3D-QSAR, molecular dynamics simulations combined with pharmacokinetic predictions.
Hanwarinroj C; Thongdee P; Sukchit D; Taveepanich S; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
J Mol Graph Model; 2022 Sep; 115():108231. PubMed ID: 35667143
[TBL] [Abstract][Full Text] [Related]
37. Antimycobacterial, docking and molecular dynamic studies of pentacyclic triterpenes from Buddleja saligna leaves.
Singh A; Venugopala KN; Khedr MA; Pillay M; Nwaeze KU; Coovadia Y; Shode F; Odhav B
J Biomol Struct Dyn; 2017 Sep; 35(12):2654-2664. PubMed ID: 28278765
[TBL] [Abstract][Full Text] [Related]
38. Homology modeling and molecular docking simulation of some novel imidazo[1,2-a]pyridine-3-carboxamide (IPA) series as inhibitors of Mycobacterium tuberculosis.
Abdullahi M; Adeniji SE; Arthur DE; Haruna A
J Genet Eng Biotechnol; 2021 Jan; 19(1):12. PubMed ID: 33474593
[TBL] [Abstract][Full Text] [Related]
39. Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration.
van der Westhuyzen R; Winks S; Wilson CR; Boyle GA; Gessner RK; Soares de Melo C; Taylor D; de Kock C; Njoroge M; Brunschwig C; Lawrence N; Rao SP; Sirgel F; van Helden P; Seldon R; Moosa A; Warner DF; Arista L; Manjunatha UH; Smith PW; Street LJ; Chibale K
J Med Chem; 2015 Dec; 58(23):9371-81. PubMed ID: 26551248
[TBL] [Abstract][Full Text] [Related]
40. New synergistic benzoquinone scaffolds as inhibitors of mycobacterial cytochrome bc1 complex to treat multi-drug resistant tuberculosis.
Chilamakuru NB; Vn AD; G VB; Pallaprolu N; Dande A; Nair D; Pemmadi RV; Reddy Y P; Peraman R
Eur J Med Chem; 2024 Jun; 272():116479. PubMed ID: 38733886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
